Rafael (RFL) said Wednesday that its $25 million rights offering resulted in subscriptions for 3.13 million class B common shares at an exercise price of $1.28 per share, generating gross proceeds of about $4 million.
Rafael's president and CEO, Howard Jonas, and his affiliates will purchase the unsubscribed shares for an aggregate amount of about $21 million.
Jonas said the proceeds will provide additional capital for regulatory approval efforts and the potential launch of Trappsol Cyclo, contingent on a positive interim result from the 48-week interim analysis of the phase 3 clinical trial for Niemann-Pick Disease Type C1.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。